SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Mutation D104N

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

There is one clinical trial.

Clinical Trials


1 Retrospective Analysis of Endostatin Genotype in Prostate Cancer Patients to Assess the Association of a Single Nucleotide Polymorphism (D104N) in Endostatin and Prostate Cancer

RATIONALE: Studying samples of blood from patients with cancer and from healthy participants in the laboratory may help doctors learn more about changes that may occur in DNA. PURPOSE: This laboratory study is looking at blood samples from patients with prostate cancer and from healthy participants to identify a polymorphism that may help in the study of prostate cancer.

NCT00900185 Prostate Cancer Genetic: mutation analysis Genetic: polymerase chain reaction Genetic: polymorphism analysis
MeSH:Prostatic Neoplasms
HPO:Prostate cancer Prostate neoplasm

Retrospective Analysis of Endostatin Genotype in Prostate Cancer Patients to Assess the Association of a Single Nucleotide Polymorphism (D104N) in Endostatin and Prostate Cancer. --- D104N ---

Frequency of D104N COL18A1 polymorphism in patients with prostate cancer and in healthy participants. --- D104N ---

Frequency of D104N COL18A1 polymorphism in African-American patients with prostate cancer and in healthy participants. --- D104N ---

DISEASE CHARACTERISTICS: - Diagnosis of prostate cancer OR healthy participant - Patient enrolled on an IRB-approved clinical trial at the National Cancer Institute or Northwestern University, including, but not limited to, any of the following: - NCI-99-C-0052 - NCI-95-C-0178 - NCI-00-C-003 - NCI-00-C-0080 PATIENT CHARACTERISTICS: - Not specified PRIOR CONCURRENT THERAPY: - Not specified DISEASE CHARACTERISTICS: - Diagnosis of prostate cancer OR healthy participant - Patient enrolled on an IRB-approved clinical trial at the National Cancer Institute or Northwestern University, including, but not limited to, any of the following: - NCI-99-C-0052 - NCI-95-C-0178 - NCI-00-C-003 - NCI-00-C-0080 PATIENT CHARACTERISTICS: - Not specified PRIOR CONCURRENT THERAPY: - Not specified Prostate Cancer Prostatic Neoplasms OBJECTIVES: Primary - Determine the incidence of the D104N COL18A1 polymorphism in patients with prostate cancer. --- D104N ---

Primary Outcomes

Measure: Frequency of D104N COL18A1 polymorphism in patients with prostate cancer and in healthy participants

Secondary Outcomes

Measure: Frequency of D104N COL18A1 polymorphism in African-American patients with prostate cancer and in healthy participants


HPO Nodes